Exact Sciences

About

Exact Sciences is the developer and manufacturer of Cologuard, a non-invasive screening test for the early detection of colorectal cancer.

Madison,Wisconsin,United States
501 - 1000
http://exactsciences.com

Highlights

Details

Last Funding Type: Post-IPO Debt
Last Funding Money Raised: $850M
Industries: Biotechnology,Health Diagnostics,Manufacturing
Founded date: Jan 1, 1995
Number Of Employee: 501 - 1000
Operating Status: Active
Stock Symbol: nasdaq:EXAS
Legal Name: Exact Sciences Corp.
Investor Type: Venture Capital

Exact Sciences is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA (sDNA) technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

4

$1.08B

Exact Sciences has raised a total of $1.08B in funding over 2 rounds. Their latest funding was raised on Feb 24, 2020 from a Post-IPO Debt round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Feb 24, 2020	Post-IPO Debt	$850M	—	—	—	Detail
Jul 24, 2015	Post-IPO Equity	$174M	—	—	—	Detail
Jun 15, 2009	Post-IPO Equity	$8.20M	1	—	—	Detail
Jan 31, 2001	IPO	$56M	—	—	—	Detail

Investments

Number of Investments

Number of Lead Investments

1

0

Exact Sciences has made 1 investments. Their most recent investment was on Jul 29, 2020, when Thrive Earlier Detection raised $257M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
Jul 29, 2020 Thrive Earlier Detection	Series B	$257M	Biotechnology	—

Investors

Number of Lead Investors

Number of Investors

—

1

Exact Sciences is funded by 1 investors. Excel Venture Management are the most recent investors.

Investor Name	Lead Investor	Funding Round
Excel Venture Management	—	Post-IPO Equity

Employee Profiles

Number of Employee Profiles

19

Exact Sciences has 19 current employee profiles, including Executive Scott Coward

Executive

Executive

Executive

Executive

Executive

Exits

Exact Sciences has had 1 exits. Exact Sciences most notable exits include Thrive Earlier Detection

Date	Company Name	Exit Type	Industry
Oct 27, 2020	Thrive Earlier Detection	M&A	Biotechnology	Detail

Acquisition

Exact Sciences has acquired 12 organizations. Their most recent acquisition was Sampleminded on Aug 1, 2017. They acquired Sampleminded for $3.20M.

Date Company Name	Industry	Acquisition Type	Price
Aug 1, 2017 Sampleminded	Biotechnology	acquisition	$ 3.20M	Detail
Feb 4, 2018 Armune BioScience	Biotechnology	acquisition	—	Detail
Oct 18, 2018 Biomatrica	Biotechnology	acquisition	—	Detail
Jul 29, 2019 Genomic Health	Biotechnology	acquisition	$ 2.80B	Detail
Mar 3, 2020 Paradigm Diagnostics	Biotechnology	acquisition	—	Detail